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The present investigation is aimed to develop self-microemulsifying drug delivery system (SMEDDS) to 
improve the in vitro dissolution of a BCS (Biopharmaceutical Classification System) class II anti emetic 
agent, domperidone. Solubility study was performed to identify the ingredients showing highest solubility 
of domperidone. The ternary phase diagrams were plotted for selected components to identify the area 
of microemulsion existence. D-optimal mixture experimental design was applied to optimize a liquid 
SMEDDS using formulation variables; the oil phase X1 (Oleic acid), the surfactant X2 (Labrasol) and the 
co-surfactant X3 (Transcutol HP). The liquid SMEDDS were evaluated for droplet size, emulsification 
time, % transmittance and drug release. Stability study was performed at 40 °C/75% RH. Liquid 
formulation was solidified by adsorption on carrier Aerosil 300. Solid SMEDDS was evaluated and 
compared with liquid SMEDDS and marketed formulation. Oleic acid was selected as oil, Labrasol as 
surfactant and Transcutol HP as co-surfactant for formulation of SMEDDS. The optimized batch showed 
best results in terms of smaller droplet size (<170 nm), emulsification time (<40 s) and drug release 
(>85% in 15 min) and was stable for 3 months. Solid SMEDDS containing Aerosil 300 showed good 
flow properties and uniform drug content. XRPD study revealed that the crystalline drug was converted 
to amorphous form in solid SMEDDS. The rate and extent of drug dissolution from solid SMEDDS 
was significantly higher than pure drug and commercial tablet formulation. The results demonstrate the 
potential of SMEDDS as a means of improving solubility, dissolution and hence the bioavailability.
Uniterms: Domperidone/self-microemulsifying delivery. Self-microemulsifying drug delivery system/
development. Biopharmaceutical Classification System.
O presente estudo teve como objetivo desenvolver sistemas de liberação auto-microemulsificantes 
(Self-Microemulsifying Drug Delivery System - SMEDDS) de domperidona, agente antiemético, classe 
II, segundo o sistema de classificação Biofarmacêutica, para melhorar sua dissolução in vitro. Estudo 
foi realizado para identificar os componentes que revelaram maior solubilidade da domperidona. 
Determinaram-se os diagramas de fase ternários para esses componentes selecionados tendo em vista 
a identificação da região de formação da microemulsão. O planejamento experimental foi empregado 
para otimizar os SMEDDS líquidos, utilizando as seguintes variáveis de formulação: a fase oleosa X1 
(ácido oleico), o agente tensoativo X2 (Labrasol) e co-tensoativo X3 (Transcutol HP). Os SMEDDS 
líquidos foram avaliados quanto às seguintes características: tamanho da gota, tempo de emulsificação,% 
de transmitância e liberação do fármaco. O estudo de estabilidade foi realizado a 40 °C/75% de umidade 
relativa. A formulação foi convertida em forma sólida por sua adsorção em Aerosil 300. Os SMEDDS 
sólidos foram avaliados e comparados com SMEDDS líquidos e a formulação comercializada. O ácido 
oléico foi selecionado para a fase oleosa, Labrasol como agente tensoativo e Transcutol como co-tensoativo 
para a formulação de SMEDDS. O lote otimizado mostrou os melhores resultados: menor tamanho de 
gota (<170 nm), menor tempo de emulsificação (<40 segundos), e de liberação do fármaco (> 85% em 
15 min). Além disso, a formulação otimizada manteve-se estável no período de 3 meses. Os SMEDDS 
sólidos contendo Aerosil 300 apresentaram boas propriedades de fluxo e uniformidade de conteúdo do 
P. Laddha, V. Suthar, S. Butani92
fármaco. O estudo de difração de raios-X revelou que o fármaco cristalino foi convertido para a forma 
amorfa, nos SMEDDS sólidos. A velocidade de dissolução do fármaco a partir dos SMEDDS sólidos 
foi significativamente maior, quando comparado ao fármaco livre e à formulação de comprimidos 
comercial. Os resultados demonstram o potencial dos SMEDDS como meio para melhorar a solubilidade, 
a dissolução e, consequentemente, a biodisponibilidade da domperidona.
Unitermos: Domperidona/liberação automicroemulsificante. Sistemas de liberação automicroemulsificante. 
Sistema de Classificação Biofarmacêutica.
INTRODUCTION
Majority of new chemical entities are found to be 
poorly water soluble in nature. To deliver such drugs in 
better way, the issue of poor aqueous solubility needs 
to be addressed by formulation scientist. Use of lipids 
has been explored in different ways recently to improve 
the bioavailability of poorly water soluble drugs. The 
unbeaten examples include simple oily solution, emulsion, 
microemulsion, nanoemulsion, micellar solution and 
more recently self-microemulsifying drug delivery 
systems (SMEDDS) (Hauss, 2007). The SMEDDS is 
advantageous over conventional emulsion in terms of 
easy manufacturing, scale up and good physical stability.
Fundamentally, a SMEDDS is mixture of natural/
synthetic oil(s), solid/semisolid surfactant(s) ideally 
isotropic sometimes containing co-solvent(s) which 
upon introduction into aqueous phase, readily emulsifies 
to produce fine oil in water microemulsion. This whole 
emulsification procedure requires very little agitation, 
same as the peristaltic motion prevailing in the gut. 
SMEDDS produce droplets having size less than 100 nm 
(Colin, 1985). In comparison to traditional emulsion 
formulations which are thermodynamically unstable 
dosage forms and require high energy input, SMEDDS are 
kinetically stable and spontaneous in emulsion formation. 
The salient features of SMEDDS include: (a) Enhanced 
oral bioavailability enabling reduction in dose, (b) More 
consistent temporal profiles of drug absorption, (c) 
Selective targeting of drug(s) towards specific absorption 
window in GIT, (d) Protection of drug(s) from the hostile 
environment in gut, (e) Control of delivery profiles, (f) 
Reduced variability including food effects, (g)High drug 
payloads, (h)possibility of autoclaving(Charman et al., 
1992). Further, the SMEDDS is believed to increase 
oral absorption via any of the following mechanisms: 
(a) Retardation of gastric transit time, (b) increase in 
effective drug solubility in lumen (c), lymphatic transport 
of the drug, (d) enterocyte based drug transport and, 
(e) increasing membrane permeability (Poelma, Breãs. 
Tukker, 1990; Poelma et al., 1991; Shah et al., 1994; 
Porter, Charman, 2001; Porter, Trevaskis, Charman, 
2007).This facet of SMEDDS makes them stand alone 
in the category of oral lipid based formulations. Several 
SMEDDS of BCS class II drugs i.e. acyclovir (Patel, 
Sawant, 2007), carvedilol (Mahmoud, Bendas, Mahmoud, 
2009), coenzyme Q10 (Kommuru et al., 2001), ezetimibe 
(Dixit, Nagarsenker, 2008), nimodipine (Kale, Patravale, 
2008), simvastatin (Patil, Patil, Paradkar, 2007) etc are 
well reported in various reputed literature.
However, the solid dosage forms have been the 
favourite dosage form for manufacturers and patients 
as well. Anything that comes as solid form is well 
accepted in terms of performance and stability. The liquid 
SMEDDS pre-concentrate present a problem of leakage 
of drug from capsule and it may also lead to dehydration 
of capsule cell. Another issue with liquid SMEDDS 
is that solubilization of a complete dose of drugs in 
single capsule volume suitable for oral administration 
is sometimes not possible. The liquid pre-concentrate 
can be mixed along with some solid and/or semisolid 
excipients to prepare solid dispersions. Solid carriers can 
be microporous inorganic substances, high surface-area 
colloidal inorganic adsorbent substances, cross-linked 
polymers or nanoparticle adsorbents. For example, silica, 
silicates, colloidal silicon dioxide, magnesium trisilicate, 
magnesium hydroxide, talcum, crospovidone, cross-
linked sodium carboxy methyl cellulose and cross linked 
polymethyl methacrylate are typical solid carriers.
In the present investigation, domperidone, a well-
known antiemetic drug with low oral bioavailability 
(about 15%), was taken as a candidate drug. This is due 
to poor solubility and extensive first pass metabolism in 
the gut wall and liver. Furthermore it is reported that, the 
bioavailability of domperidone is enhanced in normal 
subjects when taken after a meal, which indicates that 
fat may enhance absorption through lymphatic system 
and thus increase bioavailability (Mueller et al., 1994). 
Hence in present study, oil, surfactant and co-surfactant 
were selected having high drug solubility followed by 
formulation region optimization by D optimal design. 
Solidification was done by using suitable adsorbent so 
as to get advantage of unit dosage form and improved 
stability.
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MATERIAL AND METHODS
Material
Domperidone was gifted by Torrent Research 
Centre, Ahmedabad. Labrasol, Transcutol HP and 
Lauroglycol were provided by Gattefosse, France as 
gift sample. Cremophor EL and Soluphor P were kindly 
gifted by BASF, Germany. Isopropyl myristate and Oleic 
acid were purchased from Central Drug House pvt. Ltd., 
India. All other chemicals and reagents used were of 
pharmaceutical grades.
Methods
Solubility studies
The solubility of domperidone in various oils, 
surfactants, and co-surfactants was determined using the 
method reported by Basalious et al. (2010). Two grams of 
each selected vehicle was added to each vial containing 
known excess of domperidone (500 mg). After sealing, 
the mixture was heated at 40 °C in water-bath for 15 min 
to facilitate the solubilization and mixed using a vortex 
mixer. Mixtures were shaken on shaker bath at 30±0.5 °C 
for 48 h. After reaching equilibrium, the mixtures 
were centrifuged using refrigerated centrifuge (Remi, 
C 24 BL) at 3000 rpm for 15 min, then 0.5 mL supernatant 
was taken with glass micropipette, and the content of 
domperidone was quantified by UV-Visible double beam 
spectrophotometer (Shimdzu UV 1800 corporation, Japan) 
at 286 nm after dilution with methanol.
Construction of pseudo-ternary phase diagram
Based on higher drug solubility ternary phase 
diagram was developed for selected oil, surfactant and 
co-surfactant (Table I). Three variables (factor) used were 
oil, water and mix of surfactant and co-surfactant (Smix) in 
specific ratio (ie.1:1, 1:2, 2:1). Ternary phase diagram was 
developed using aqueous titration method (Gupta, Mishra 
et al., 2011; Kumar et al., 2011). Slow titration with 
aqueous phase was done to each weight ratio of oil and 
Smix and visual observation was carried out for formation 
of transparent and easily flowable o/w micro emulsion. 
The physical state of the micro emulsion was marked 
on a pseudo-three-component phase diagram with one 
axis representing aqueous phase, the other representing 
oil and the third representing a mixture of surfactant and 
co-surfactant at fixed weight ratios (Smix 1:1). The phase 
boundary was determined by observing the change in 
sample appearance from transparent to turbid. The phase 
diagram was constructed by using sigma plot 12 software. 
TABLE I - Solubility of domperidone in various excipients
Excipient Solubility (mg/mL)
Oils
Oleic acid
Triacetin
Soya oil
Corn oil
Glycerol mono oleate
Isopropyl myristate
74.9
0.01
0.37
0.2
2.55
0.01
Surfactants/Co-surfactants
Lauroglycol
Transcutol HP
Labrasol
Poly Ethylene Glycol-400
Propylene Glycol
Cremophor EL
Tween-80
Pluronic F-68
Soluphor P
Span 80
11.62
70.58
35.9
3.79
2.53
38.55
36.6
0.018
7.62
6.9
Similarly ternary phase diagrams were prepared for other 
ratios of surfactant and co-surfactant like 1:2, 2:1, 3:1, 
4:1, 5:1, 6:1 etc.
Preparation of SMEDDS
A constant amount of drug was dissolved in oil 
using vortex mixer (Remi Motors Ltd., India). Required 
amount of surfactant and co-surfactant were added to the 
mixtures and further mixed using vortex mixer. These 
mixtures were warmed to 40 °C using a water bath for 30 
mins with intermittent shaking to ensure complete mixing. 
The formulations were evaluated for emulsification time, 
percent transmittance, droplet size and in vitro drug 
release.
Evaluation of SMEDDS
• Emulsification time and transmittance
The SMEDDS formulation (0.1 mL) was introduced 
into 100 mL of 0.1 N HCl under action of propeller stirrer 
at constant speed of 100 rpm at 37±5 °C temperature. 
Emulsification time was measured by visual observation 
and percent transmittance was measured at 650 nm 
through UV spectrophotometer(Trull et al., 1994)
• Droplet size
Hundred milligram of each formulation was 
introduced into 100 mL of 0.1 N HCl at 25 °C and the 
contents were gently stirred using a propeller stirrer. The 
droplet size of the resultant emulsion was determined 
by photon correlation spectroscopy using a Mastersizer 
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2000 (Malvern Instruments, UK) which can measure 
sizes between 10 and 5000 nm (Patil, Joshi, Paradkar, 
2004).
• In vitro dissolution studies
In vitro drug release study was carried out using USP 
type II (Paddle type) dissolution apparatus. SEMDDS 
containing 10 mg of domperidone was filled in HPMC 
capsules (size “00”) and introduced into 900 mL of a 
dissolution medium 0.1 N HCl and maintained at 37±0.5 °C. 
The Revolution speed of the paddle was kept constant at 
50 rpm. The aliquot of 5 mL was withdrawn at 5, 10, 15, 
30, 45, and 60 min and filtered through 0.45 µm membrane 
filters. The concentration of domperidone was determined 
spectrophotometrically at 284 nm. The dissolution profile 
of developed optimized batch was compared with pure drug 
and marketed preparation Domcolic®.
Formulation optimization of SMEDDS using D 
optimal design
The mixture experimental study was designed 
based on a three component system: the oil X1 (Oleic 
acid), the surfactant X2 (Labrasol) and the co-surfactant 
X3 (Transcutol HP). Based on the previous result obtained 
from phase diagram, the range of X1 was selected as 10-
30% and that of X2 and X3 was selected as 35-45%. Values 
of independent variables were introduced into the Design-
Expert version 8 software and batch matrix was derived. 
Sixteen batches were prepared as mentioned above and 
evaluated (Table II). The emulsification time (Y1), mean 
droplet size (Y2) and cumulative amount of drug released 
after 15mins (Y3) were used as the responses.
Formulation of solid SMEDDS
Adsorption on solid carrier is easy and reliable 
method to convert liquid SMEDDS into solid SMEDDS 
(Agarwal et al., 2009). Silicon dioxide shows high 
adsorption capacity and its permitted safe concentration 
as per Inactive Ingredients Guide of USFDA is 100 mg. 
The liquid SMEDDS was added drop wise over the solid 
adsorbent in a broad porcelain dish. After each addition, 
the mixture was homogenized using glass rod to ensure 
uniform distribution of the formulation. The resultant 
damp mass was passed through sieve no. 120, dried at 
ambient temperature and evaluated for flow property, 
compressibility, particle size distribution and in vitro drug 
release. Optimized formulation was characterized for 
X-Ray Powder Diffraction study so as to identify the state 
of drug and also subjected to stability study at 40 °C/70% 
RH for 3 months (Oh et al., 2011).
TABLE II - Formulation and Characterisation of D optimal mixture design batches
Batch no
Oleic acid 
(µL) 
X1
Labrasol 
(µL) 
X2
Transcutol HP 
(µL) 
X3
Emulsification 
time (sec.) 
Y1
Mean droplet 
size (nm) 
Y2
Drug released in 
15 min 
Y3
P1 200.00 450.00 350.00 100 428.4 83.83
P2 100.00 450.00 450.00 32 150.0 87.96
P3 132.87 450.00 417.13 39 250.0 72.06
P4 100.00 450.00 450.00 29 168.0 87.45
P5 133.77 414.23 450.00 45 213.0 72.90
P6 300.00 350.00 350.00 115 712.7 66.75
P7 235.38 350.00 414.62 120 586.1 82.91
P8 175.10 374.90 450.00 45 211.0 81.27
P9 204.76 404.49 390.75 75 438.5 67.37
P10 235.38 350.00 414.62 113 591.0 80.02
P11 200.00 450.00 350.00 93 432.0 84.30
P12 169.07 444.72 386.21 57 232.0 68.04
P13 168.15 411.85 420.00 51 233.0 69.52
P14 175.10 374.90 450.00 42 210.0 80.56
P15 300.00 350.00 350.00 120 721.6 63.69
P16 254.34 395.66 350.00 112 617.1 82.95
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RESULT AND DISCUSSION
An effective SMEDDS is the one which emulsifies 
spontaneously to generate oil droplets enclosing the 
dissolved drug and which also solubilizes the drug in given 
dissolution medium rapidly and completely. Keeping these 
criteria in mind, the study was designed in such a way that 
the results can ensure the behavior of the drug delivery 
system in vivo. Here, non-ionic surfactants were used in 
the study since they are known to be less affected by pH 
and changes in ionic strength.
Solubility study
Result of solubility studies on domperidone in 
various oils, surfactants and co-surfactants are presented 
in Table I. Oleic acid showed highest drug solubility 
(74.9 mg/mL) and no other oil showed comparable 
solubility and hence only Oleic acid was selected as oil 
phase for domperidone SMEDDS formulation. Transcutol 
HP showed highest drug solubility (70.58 mg/mL) 
and good solubility was also observed in cremophor 
EL (38.55 mg/mL), Tween-80 (36.6 mg/mL), Labrasol 
(35.9 mg/mL). Hence Transcutol HP was selected 
as cosurfactant and the other three were selected as 
surfactants for development of phase diagram.
Pseudo-ternary phase diagrams
SMEDDS formulation should be simple and safe, 
prepared using nontoxic surfactants as well as pseudo 
ternary phase diagrams shows high region of formulation 
(Kang, Lee et al., 2004). On the basis of the solubility 
study of domperidone, oleic acid was used as the oil 
phase and Transcutol HP was used as the co-surfactant. 
All three surfactants showed higher monophasic region 
in 1:1 ratio with Transcutol HP. Figures 1, 2 and 3 show 
phase diagrams for Cremophor EL, Labrasol and Tween 
80 respectively. Labrasol showed higher monophasic 
region as compared to Cremophor EL and Tween 80 and 
hence it was further used for formulation of SMEDDS of 
domperidone.
Preparation and evaluation of SMEDDS
From the results of phase diagrams, Oleic acid, 
Labrasol and Transcutol HP were finalised as oil, surfactant 
and co-surfactant respectively. As formulation ingredients 
are selected, SMEDDS was prepared incorporating 10 mg 
drug. Sixteen batches were prepared and evaluated as 
showed in Table II. Emulsification time was assessed 
FIGURE 1 - Pseudo-ternary phase diagrams of Cremophor EL 
as surfactant in 1:1 ratio with Transcutol HP.
FIGURE 2 - Pseudo-ternary phase diagrams of Labrasol as 
surfactant in 1:1 ratio with Transcutol HP.
FIGURE 3 - Pseudo-ternary phase diagrams of Tween 80 as 
surfactant in 1:1 ratio with Transcutol HP.
visually. If formulation is microemulsion, emulsification 
takes place within a minute on addition of it into water. 
Emulsion formulation in batches P2, P3, P4, P5, P8, P12, 
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P13 and P14 required time less than a minute which is 
indicative of micron size of globules. Furthermore the 
emulsions of these batches were clear with bluish tinge 
and stable. Generally the formulation can be termed 
microemulsion only if the globule size in less than 300 nm. 
Batches P1, P6, P7, P9, P10, P11, P15 and P16 showed 
higher globule size and low clarity. 
Percentage transmittance can be used to reflect clarity 
and micron size of globule. The average transmittance 
observed of all the prepared batches was around 80% while 
batches P2 and P4 showed highest (90%) transmittance.
From the globule size analysis it was concluded that 
batches P2 and P4 has smaller globule size as compared 
to other batches, as these batches contained only 10% 
oil. As the concentration of oil increases the globule size 
increase whereas increasing the amount of surfactant and 
co-surfactant leads to decrease in globule size.
In vitro drug release showed that more than 75% 
drug got released from all batches within 60 min which 
indicates the solubility enhancing potential of SMEDDS 
formulations. Drug release at 15min was compared and as 
expected, batches P2 and P4 showed higher drug release 
(˃85%) in 15 min due to lower oil content and higher 
content of surfactant and co-surfactant.
Optimization of SMEDDS
The emulsification time of all sixteen batches are 
presented in Table II. The emulsification time was ranged 
from 29s to 120s, which indicate that all the batches 
quickly converted into microemulsion on exposure to 
aqueous media. The selected special quadratic model 
was used to generate the following equation for the 
emulsification time:
Y1 = 116.70X1 – 29.14X2 – 163.46X3 + 202.16X1X2 + 
405.42X1X3 + 508.57X2X3 – 2653.28X12X2X3 – 
1015.06X1X22X3 – 141.67X1X2X32  (1)
Figure 4 indicates the effect of Oleic acid, Labrasol 
and Transcutol HP on emulsification time. It can be 
observed from the plot that emulsification time may 
increase with the increase in amount of Oleic acid and 
may decrease with the increase in amount of Labrasol 
and Transcutol HP. The P value of 0.05 for any factor in 
analysis of variance (ANOVA) indicates significant effect 
of the corresponding factor on the emulsification time (Y1). 
It can be inferred that the interaction term X1X2, X1X3, 
X2X3, X1X22X3 and X1X2X32 have non-significant effect on 
the emulsification time. The only interaction term X1
2X2X3 
has a significant antagonistic effect on emulsification time 
as indicated by the negative value of the coefficient. Thus 
we can conclude that emulsification time increase by high 
concentration of oil (X12).
The mean droplet size was selected as another 
response and is presented in Table II. The mean droplet 
size was ranged between 150 nm to 721.56 nm, which 
indicates that the response was sensitive towards the 
studied factor. The equation for the mean droplet size is 
as mentioned underneath:
Y2 = 715.75X1 – 314.15X2 – 1454.35X3 + 894.08X1X2 + 
1613.06X1X3 + 4197.63X2X3 – 12553.09X12X2X3 – 
10897.00X1X22X3 – 5484.62X1X2X32  (2)
As indicated in Figure 5, it was observed that the 
mean droplet size may increase with the increase in 
amount of Oleic acid and may decrease with increase in the 
amount of Labrasol and Transcutol HP. From the P value of 
0.05 in ANOVA, it can be inferred that the interaction term 
X1X2, ,X1X22X3 and X1X2X32 have non-significant effect 
on the mean droplet size. The interaction term X1X3 and 
X2X3 have a significant positive synergistic effect on mean 
droplet size and term X12X2X3 has a significant antagonistic 
effect on mean droplet size indicated by the negative value 
of the coefficient. Thus we can conclude that droplet size 
also increase with increase in oil concentration.
The drug released at 15min was ranged between 
FIGURE 4 - Response surface plot of emulsification time (Y1) 
versus three factors (X1 = Oleic acid, X2 = Labrasol, X3 = 
Transcutol HP).
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63.69 % and 87.96 %, which indicated that it is also 
affected by the concentration of all three ingredients. The 
equation for the drug released at 15min is as below:
Y3 = 65.48X1 + 53.72X2 + 103.83X3 + 10.81X1X2 + 
18.85X1X3 + 34.95X2X3 – 680.67X12X2X3 – 
712.17X1X22X3 – 516.88X1X2X32  (3)
It can be observed from the Figure 6 that drug 
released after 15 mins may decrease with the increase in 
amount of Oleic acid and may increase with the increase 
in the amount of Labrasol and Transcutol HP. Results of 
ANOVA show that the (P value >0.05) interaction term 
X1X3, X2X3, X1 X22X3 and X1X2 X32 have non-significant 
effect on the drug released after 15 mins. The interaction 
term X1X2 have a significant positive synergistic effect on 
drug released after 15 mins and X12X2X3 have a significant 
antagonistic effect on drug released after 15 mins indicated 
by the negative value of the coefficient.
It is clear from the developed equations that optimum 
response in terms of lower emulsification time (<40 s), 
smaller droplet size (<170 nm) and higher drug release 
(>85% in 15 mins) was achieved at low concentrations 
of oil and higher concentrations of surfactants and co 
surfactant. Hence optimized batches, P2 and P4 containing 
10% of oil 45% of surfactant and co-surfactant showed the 
responses (Y1=32 and 29, Y2=150 and 168, Y3=87.96 and 
FIGURE 5- Response surface plot of mean droplet size (Y2) 
versus three factors (X1 = Oleic acid, X2 = Labrasol, X3 = 
Transcutol HP).
87.45) which were in close agreement with the predicted 
ones (30.862, 165.32 and 87.503 respectively). Therefore 
the developed model was found reliable.
Solidification of SMEDDS
In present study two grades of colloidal silicon 
dioxide, Aerosil 200 (20% to 30%) and Aerosil 300 (20% 
to 40%) were used. Five batches were prepared and 
evaluated (Table III). Batches SP1 and SP3 containing 
20% of Aerosil 200 and Aerosil 300 respectively were 
adhesive and showed poor flow property. Thus 20% of 
carrier is not enough for formulation of free flowing 
solid mass. Batches SP2 and SP4 containing 30% carrier 
showed good compressibility, flow property and dry mass 
produced can easily be filled in “size 00” HPMC capsule. 
Hence it was concluded that 30% carrier was enough 
for formation of solid SMEDDS of domperidone. In 
comparison to batch SP2, batch SP4 containing Aerosil 
300 showed better flow properties which indicate that 
Aerosil 300 is having better adsorption capacity. Batch 
SP5 containing 40% adsorbent showed that the mass 
produced cannot be filled in “size 00” HPMC capsule. 
Further it increases the cost of formulation and hence 
we can conclude that concentration of carrier should be 
optimized. Batch SP4 showed 200.6 nm mean droplet size 
after emulsion formation and 84.79% transmittance which 
are well accepted and comparable to liquid SMEDDS. 
FIGURE 6- Response surface plot of drug released after 15 min 
(Y3) versus three factors (X1 = Oleic acid, X2 = Labrasol, X3 = 
Transcutol HP).
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Further batch SP4 was also evaluated for in vitro drug 
release and compared with liquid SMEDDS, pure drug and 
marketed product (Figure 7). Comparative drug release 
profile shows the dissolution enhancement potential of 
SMEDDS formulations. Further we can conclude that 
solidification did not affect the selected responses specially 
the in vitro drug release profile.
 
Batch SP4 and pure drug were analysed to check 
the crystallinity by X-Ray Powder Diffraction (Figure 
8). It can be concluded from the result that pure drug is in 
crystalline form and it is converted into amorphous state 
when formulated in SMEDDS which may be responsible 
for higher drug solubility. Accelerated stability study 
after 3 months showed comparable drug release and 
assay. Further the study should continue for 6 months to 
conclude about the stability of formulated domperidone 
solid SMEDDS.
CONCLUSION
Solid SMEDDS is one of the recent approaches 
for formulation of unit dosage form for drugs with low 
aqueous solubility. Selection of oil and surfactant, co 
surfactant blend is crucial and vary from drug to drug 
based on solubility study. The liquid SMEDDS pre 
concentrate was converted into solid by adsorption on to 
a carrier (Aerosil 300). The optimized solid SMEDDS 
formulation of domperidone showed significant increase in 
dissolution rate compared to marketed tablet (Domcolic®) 
and pure drug indicates the potential of SMEDDS. We can 
conclude from this study that solid SMEDDS formulation 
is capable to enhance solubility and dissolution of poorly 
water soluble drugs like domperidone which may result 
in improved therapeutic performance.
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TABLE III - Evaluation results of solid SMEDDS batches
Batch Bulk density 
(g/cm3)
Tapped 
density (g/cm3)
Carr’s index 
(%)
Hausner’s 
ratio
Angle of 
repose (°)
Flow 
character
Drug content 
(%)
SP1 0.33 0.48 31.3 1.45 34.26 Very poor 79.42
SP2 0.55 0.68 19.1 1.24 29.25 Fair 90.46
SP3 0.36 0.51 29.4 1.41 32.87 Poor 82.36
SP4 0.54 0.64 15.6 1.19 21.80 Good 98.87
SP5 0.49 0.56 12.5 1.14 20.80 Good 97.67
FIGURE 7 - Comparative drug release profile of pure drug, 
marketed product, liquid SMEDDS (batch P2) and solid 
SMEDDS (batch SP4).
FIGURE 8- X Ray Powder Diffractometry of pure drug, placebo 
and batch SP4.
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